Cantabio Pharmaceuticals Inc. | WebDisclosure

Switch to English

9472	Sociétés
185370	Mots-clés
117721	Articles
99262	Communiqués

Accueil
Sociétés
Cantabio Pharmaceuticals Inc.

COMMUNIQUÉ DE PRESSE

publié le 06/02/2024 à 16:00, il y a 1 année 9 mois

Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease
Cantabio Pharmaceuticals, Inc. receives major grant from MJFF for the development of DJ-1 replacement therapy aimed at treating Parkinson's disease by increasing DJ-1 levels in patients and preventing disease progression

Precision Medicine Cantabio Pharmaceuticals MJFF Grant DJ-1 Replacement Therapy Parkinson's Disease

Les Echos

Publié le 04/12/2025 à 18:14, il y a 13 heures 41 minutes

Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 55 minutes

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 55 minutes

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 14 heures 10 minutes

Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 14 heures 10 minutes

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/12/2025 à 02:35, il y a 5 heures 20 minutes

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 02:30, il y a 5 heures 25 minutes

Klondike Gold Announces AGM Results
Publié le 05/12/2025 à 01:00, il y a 6 heures 55 minutes

BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 50 minutes

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 55 minutes

NXT Energy Solutions Completes Data Acquisition for SFD Survey

Voir tout ACCESSWIRE

EQS Group

Publié le 05/12/2025 à 07:00, il y a 55 minutes

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 4 heures 25 minutes

CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 8 heures 4 minutes

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 11 heures 30 minutes

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 11 heures 40 minutes

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025